glp 1 and diabetic retinopathy The Impact of GLP-1 Receptor Agonists on Ocular Disease January Blog - GLP1s and

5 Krieger, C

Troubleshooting common PT-141 issues Solving problems and optimizing protocol

Choosing between Survodutide and Tirzepatide depends on various factors, including availability, individual health status, treatment goals, and physician recommendations

Men vs women dosing differences Men's typical dosing: Starting: 1mg Standard: 1.5mg (most common) Maximum: 2mg Sweet spot: Usually 1.5-2mg Higher doses = stronger effect but more nausea Women's typical dosing: Starting: 0.5mg Standard: 0.75-1mg (most common) Maximum: 1.5mg Sweet spot: Usually 0.75-1mg Women more sensitive (need less) Why women need less: Smaller average body weight Higher sensitivity to melanocortin activation Stronger side effects at equivalent doses Different hormonal environment FDA trials showed efficacy at lower doses Sex-specific considerations: Individual variation matters most: Sex-based guidelines are averages Some men respond to 1mg Some women need 1.5mg Track your personal response Adjusting dose based on response Signs dose is too low: Minimal or no effect on arousal No side effects either (might not have reached bloodstream?) Same as baseline sexuality Waited full 3 hours post-dose Tried 2-3 times with no response When to increase: Tolerated current dose well (minimal nausea ) Consistent lack of desired effects Increment by 0.5mg Try new dose 2-3 times before further adjusting Don't exceed maximum (2mg men, 1.5mg women) Signs dose is too high: Strong nausea (ruins experience) Vomiting (rare but possible) Flushing, feeling unwell Side effects outweigh benefits Effect is present but overshadowed When to decrease: Side effects too strong Reduce by 0.25-0.5mg Try lower dose 2-3 times Find balance between efficacy and tolerance Some prefer mild effect with no nausea vs strong effect with sickness Dose response curve: Long-term dosing patterns: Most settle on one dose after 3-5 trials Occasionally adjust based on circumstance Tolerance doesn't typically develop No need for cycling or breaks Can use as needed indefinitely Injection technique for PT-141 Proper subcutaneous administration